Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monzosertib in R/R AML or High-Risk MDS
NCT07780565Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2027
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of monzosertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Treatment Emergent Adverse Events, Dose Limiting Toxicities and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
monzosertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07780565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780565.